Literature DB >> 9576641

Clinical presentation and therapeutic outcome in 26 patients with primary CNS lymphoma.

U Herrlinger1, M Schabet, M Clemens, R D Kortmann, D Petersen, B E Will, R Meyermann, J Dichgans.   

Abstract

This retrospective study analyzes clinical features and therapeutic outcome in 26 immunocompetent patients with primary central nervous system lymphoma (PCNSL). Most patients presented with personality changes. PCNSL lesions were mainly iso- or hyperdense, enhancing lesions on CT scan, hypointensive on T1-, and hyperintensive on T2-weighted MRI. Multiple lesions were found in about 60% of patients. Nine of 11 patients receiving radiotherapy alone showed complete remission (CR). Median survival time after diagnosis (MST) was 13 months. Seven patients received intravenous and intrathecal methotrexate, radiotherapy, and postirradiation intravenous cytarabine. Six of these patients had CR and 5 patients are alive in CR after a median follow-up of 12 months. Five patients received various other radiochemotherapy regimens (MST 6 months), and 3 patients died before receiving any radio- or chemotherapy. Our preliminary treatment results show a tendency to improved survival with radiochemotherapy. This is consistent with pertinent data from the literature which favors radiochemotherapy for patients with PCNSL.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9576641     DOI: 10.1111/j.1600-0404.1998.tb00647.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  17 in total

1.  Primary central nervous system lymphoma and subcutaneous metastases.

Authors:  B Al Bahrani; C Henderson; G Delaney
Journal:  J Neurooncol       Date:  2000-04       Impact factor: 4.130

Review 2.  Primary central nervous system lymphoma: implication of high-dose chemotherapy followed by auto-SCT.

Authors:  N Reddy; B N Savani
Journal:  Bone Marrow Transplant       Date:  2011-10-17       Impact factor: 5.483

3.  Role of rCBV values derived from dynamic susceptibility contrast-enhanced magnetic resonance imaging in differentiating CNS lymphoma from high grade glioma: a meta-analysis.

Authors:  Ruofei Liang; Mao Li; Xiang Wang; Jiewen Luo; Yuan Yang; Qing Mao; Yanhui Liu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

4.  Isolated acute vestibular syndrome due to presumed primary central nervous system lymphoma involving the dorsal medulla.

Authors:  Sun-Uk Lee; Hyo-Jung Kim; Jeong-Yoon Choi; Xu Yang; Ji-Soo Kim
Journal:  J Neurol       Date:  2018-06-23       Impact factor: 4.849

5.  Differentiation among glioblastoma multiforme, solitary metastatic tumor, and lymphoma using whole-tumor histogram analysis of the normalized cerebral blood volume in enhancing and perienhancing lesions.

Authors:  J H Ma; H S Kim; N-J Rim; S-H Kim; K-G Cho
Journal:  AJNR Am J Neuroradiol       Date:  2010-06-25       Impact factor: 3.825

6.  Ocular involvement in patients with primary CNS lymphoma.

Authors:  Jung Taeck Hong; Ju Byung Chae; Joo Yong Lee; June-Gone Kim; Young Hee Yoon
Journal:  J Neurooncol       Date:  2010-07-24       Impact factor: 4.130

Review 7.  Primary CNS lymphoma: findings outside the brain.

Authors:  U Herrlinger
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

Review 8.  Primary central nervous system lymphoma: from clinical presentation to diagnosis.

Authors:  U Herrlinger; M Schabet; M Bitzer; D Petersen; P Krauseneck
Journal:  J Neurooncol       Date:  1999-07       Impact factor: 4.130

9.  A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma.

Authors:  Kennichi Taoka; Yasushi Okoshi; Noriaki Sakamoto; Shingo Takano; Akira Matsumura; Yuichi Hasegawa; Shigeru Chiba
Journal:  Int J Hematol       Date:  2010-10-22       Impact factor: 2.490

10.  Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL.

Authors:  Brian T Farrell; Bronwyn E Hamilton; Edit Dósa; Endre Rimely; Morad Nasseri; Seymur Gahramanov; Cynthia A Lacy; Eugene P Frenkel; Nancy D Doolittle; Paula M Jacobs; Edward A Neuwelt
Journal:  Neurology       Date:  2013-06-14       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.